Nature Communications (Dec 2020)
Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells
- Clara Gómez-Aleza,
- Bastien Nguyen,
- Guillermo Yoldi,
- Marina Ciscar,
- Alexandra Barranco,
- Enrique Hernández-Jiménez,
- Marion Maetens,
- Roberto Salgado,
- Maria Zafeiroglou,
- Pasquale Pellegrini,
- David Venet,
- Soizic Garaud,
- Eva M. Trinidad,
- Sandra Benítez,
- Peter Vuylsteke,
- Laura Polastro,
- Hans Wildiers,
- Philippe Simon,
- Geoffrey Lindeman,
- Denis Larsimont,
- Gert Van den Eynden,
- Chloé Velghe,
- Françoise Rothé,
- Karen Willard-Gallo,
- Stefan Michiels,
- Purificación Muñoz,
- Thierry Walzer,
- Lourdes Planelles,
- Josef Penninger,
- Hatem A. Azim,
- Sherene Loi,
- Martine Piccart,
- Christos Sotiriou,
- Eva González-Suárez
Affiliations
- Clara Gómez-Aleza
- Oncobell, Bellvitge Biomedical Research Institute, IDIBELL
- Bastien Nguyen
- Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles
- Guillermo Yoldi
- Oncobell, Bellvitge Biomedical Research Institute, IDIBELL
- Marina Ciscar
- Oncobell, Bellvitge Biomedical Research Institute, IDIBELL
- Alexandra Barranco
- Oncobell, Bellvitge Biomedical Research Institute, IDIBELL
- Enrique Hernández-Jiménez
- Oncobell, Bellvitge Biomedical Research Institute, IDIBELL
- Marion Maetens
- Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles
- Roberto Salgado
- Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles
- Maria Zafeiroglou
- Oncobell, Bellvitge Biomedical Research Institute, IDIBELL
- Pasquale Pellegrini
- Oncobell, Bellvitge Biomedical Research Institute, IDIBELL
- David Venet
- Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles
- Soizic Garaud
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles
- Eva M. Trinidad
- Oncobell, Bellvitge Biomedical Research Institute, IDIBELL
- Sandra Benítez
- Oncobell, Bellvitge Biomedical Research Institute, IDIBELL
- Peter Vuylsteke
- Department of Medical Oncology, Université Catholique de Louvain, CHU UCL, Namur, site Sainte-Elisabeth
- Laura Polastro
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles
- Hans Wildiers
- Department of Oncology, KU Leuven-University of Leuven
- Philippe Simon
- Department of Obstetrics and Gynaecology, Erasme, Université Libre de Bruxelles
- Geoffrey Lindeman
- Peter MacCallum Cancer Centre, The Walter and Eliza Hall Institute of Medical Research and The Royal Melbourne Hospital
- Denis Larsimont
- Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles
- Gert Van den Eynden
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles
- Chloé Velghe
- Clinical Trial Supporting Unit, Institut Jules Bordet, Université Libre de Bruxelles
- Françoise Rothé
- Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles
- Karen Willard-Gallo
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles
- Stefan Michiels
- Service de Biostatistique et D’Epidémiologie, Gustave Roussy, CESP, U1018, Université Paris-Sud, Faculté de Médcine, Université Paris-Saclay
- Purificación Muñoz
- Oncobell, Bellvitge Biomedical Research Institute, IDIBELL
- Thierry Walzer
- Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS, Université Claude Bernard
- Lourdes Planelles
- BiOncotech Therapeutics, Parc Cientific Universitat
- Josef Penninger
- Life Sciences Institute, University of British Columbia
- Hatem A. Azim
- Division of Hematology/Oncology, Department of Medicine, American University of Beirut
- Sherene Loi
- Peter MacCallum Cancer Centre, The Walter and Eliza Hall Institute of Medical Research and The Royal Melbourne Hospital
- Martine Piccart
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles
- Christos Sotiriou
- Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles
- Eva González-Suárez
- Oncobell, Bellvitge Biomedical Research Institute, IDIBELL
- DOI
- https://doi.org/10.1038/s41467-020-20138-8
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 18
Abstract
Receptor activator of nuclear factor-κB (RANK)/RANK-ligand (RANKL) signaling regulates the tumor-immune crosstalk. Here the authors show that systemic RANKL inhibition promotes CD8 + T cell infiltration in patients with early breast cancer and that loss of RANK signaling in tumor cells drives a T cell-dependent anti-tumor response in preclinical models.
